Article
On-demand use of a phosphodiesterase type-5 inhibitor did not affect prostatic or urinary outcomes of therapy for BPH, a post hoc analysis of a large randomized trial showed.
FDA approves mitomycin intravesical solution for recurrent LG-IR-NMIBC
Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP
PSMA-PET imaging product, Gozellix, launches on US market
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
Dipen Parekh, M.D. named Chief Executive Officer of the University of Miami Health System
Cleveland Clinic is First to Use Wireless, Catheter-Free Device to Monitor Bladder Dysfunction in Patients